AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 26914134
Drug: Methoxamine 2
RxNorm normalized name: methoxamine 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methoxamine 2 mg with atropine 0.3 mg (Group MA3)
Trial: 20623289
Drug: 10 cc
RxNorm normalized name: CC
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 cc 1% Lignocaine at apical region (Group B)
Trial: 20623289
Drug: 5 cc
RxNorm normalized name: Syringe Unit 35 cc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 cc 1% Lignocaine at both bases (Group C)
Trial: 20623289
Drug: 4 cc
RxNorm normalized name: CC
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 cc at apex and 3 cc at both bases (Group D)
Trial: 12496753
Drug: Semisimultaneous administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Semisimultaneous administration of midazolam (5 mg orally followed by 2 mg IV after 6 hours)
Trial: 12496753
Drug: Traditional method
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional method (individual midazolam doses, 1 week apart)
Trial: 9752816
Drug: CCB or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCB or ACE inhibitor as first-line therapy
Trial: 7657846
Drug: Cibenzoline 260
RxNorm normalized name: cibenzoline
DrugBank: Cibenzoline (DB13358)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cibenzoline 260 mg/day
Trial: 2720134
Drug: Whole 240
RxNorm normalized name: Acetosella acetosella whole
DrugBank: Rumex acetosella whole (DB14166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole 240 mg verapamil sustained-release tablet
Trial: 31525490
Drug: Child care-center
RxNorm normalized name: Senna-Relief Childs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Child care-center based lessons (18-week gross motor and 12-week nutrition) administered by trained child care staff
Trial: 26984901
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment with Albendazole (ABZ) 15 mg/k/d for 10 days and Praziquantel (PZQ) 50 mg/k/d for 10 days
Trial: 26984901
Drug: Albendazole (ABZ)
RxNorm normalized name: Albendazole
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Albendazole (ABZ) alone 15 mg/k/d for 10 days
Trial: 23043965
Drug: Indirect moxibustion
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indirect moxibustion 2 times per week for 4 weeks (Treatment group A)
Trial: 23043965
Drug: Indirect moxibustion
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indirect moxibustion 3 times per week for 4 weeks (Treatment group B)
Trial: 16036041
Drug: Aldosterone blockade
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aldosterone blockade (specific drug not mentioned, but refers to Aldactone and Eplerenone)
Trial: 10557001
Drug: Salt restriction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salt restriction diet (5 grams of sodium chloride per day) with oral and written instructions from a clinical nutritionist and provision of low sodium bread (0.5%) during weeks 4-24.
Trial: 8739026
Drug: Grapefruit juice
RxNorm normalized name: grapefruit juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grapefruit juice with quinidine sulfate (400 mg)
Trial: 8739026
Drug: Water with
RxNorm normalized name: sterile water with electrolytes injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water with quinidine sulfate (400 mg)
Trial: 1902054
Drug: Thrombolytic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic therapy (Streptokinase or rt-PA)
Trial: 7132728
Drug: Cimetidine (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (400 mg) after placebo
Trial: 7132728
Drug: Metoclopramide (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide (10 mg) after Cimetidine
Trial: 7132728
Drug: Thyrotropin-releasing hormone
RxNorm normalized name: thyrotropin-releasing hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyrotropin-releasing hormone (25 micrograms) after placebo or Met
Trial: 27046445
Drug: Trabodenoson (200,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trabodenoson (200, 400, 800, 1,600, 2,400, or 3,200 μg)
Trial: 24861853
Drug: USL255 (topiramate)
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: USL255 (topiramate) extended-release capsules, single doses ranging from 25-1,400 mg
Trial: 17909382
Drug: Designed delays
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Designed delays (DD) trial of reduced restrictions on Cox-2 inhibitors
Trial: 16330739
Drug: Ventilation tube
RxNorm normalized name: Sus scrofa fallopian tube preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ventilation tube (VT) treatment
Trial: 16330739
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment (no ventilation tubes)
Trial: 11986409
Drug: Beta-blocker therapy
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blocker therapy (metoprolol or carvedilol)
Trial: 9455713
Drug: Carbamazepine slow-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbamazepine slow-release formulation with food
Trial: 9455713
Drug: Carbamazepine slow-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbamazepine slow-release formulation without food (12-hour fast)
Trial: 9455713
Drug: Carbamazepine slow-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbamazepine slow-release formulation (both conditions)
Trial: 30617388
Drug: 3% prilocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% prilocaine with felypressin 0.03 I.U. per ml
Trial: 29433613
Drug: Indicated medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indicated medication for schizophrenia or mood disorders along with usual prayer camp activities (prayers, chain restraints and fasting)
Trial: 29433613
Drug: Prayer camp
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prayer camp activities alone (no medication)
Trial: 23046709
Drug: Intranasal 17β
RxNorm normalized name: NALOXONE RESCUE KIT INTRANASAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal 17β estradiol 3 mg/day for two months + 200 mg/day of micronized progesterone by vaginal route 14 days/month (E2+P)
Trial: 23046709
Drug: Percutaneous 17β
RxNorm normalized name: PERCUTANEOUS INTRODUCER SET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percutaneous 17β estradiol gel 1.5 mg/day for three months + 200 mg/day of micronized progesterone by vaginal route 14 days/month (E2+P)
Trial: 23046709
Drug: Intranasal 17β
RxNorm normalized name: NALOXONE RESCUE KIT INTRANASAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal 17β estradiol 3 mg/day for two months (E2)
Trial: 23046709
Drug: Percutaneous 17β
RxNorm normalized name: PERCUTANEOUS INTRODUCER SET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percutaneous 17β estradiol gel 1.5 mg/day for three months (E2)
Trial: 19578221
Drug: Standard program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard program of intensive therapy
Trial: 17804681
Drug: Recruitment to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recruitment to a clinical trial (no change in therapy)
Trial: 11241092
Drug: 30 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/kg intravenous methylprednisolone during sternotomy and 30 mg/kg during initiation of cardiopulmonary bypass
Trial: 11241092
Drug: 15 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/kg methylprednisolone at the same 2 times
Trial: 11241092
Drug: Isotonic sodium
RxNorm normalized name: ISOTONIC SODIUM CHLORIDE SOLUTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic sodium chloride solution at the same 2 times
Trial: 9706371
Drug: Idebenone 300
RxNorm normalized name: idebenone 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idebenone 300 mg t.i.d.
Trial: 9706371
Drug: Idebenone (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idebenone (various dosages from 60 mg to 300 mg t.i.d.)
Trial: 9706371
Drug: Piracetam 800
RxNorm normalized name: piracetam 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piracetam 800 mg t.i.d.
Trial: 1396833
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg of full length unglycosylated single‐chain‐urokinase plasminogen activator (saruplase)
Trial: 277069
Drug: 10 per
RxNorm normalized name: 10 Person ANSI KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 per cent urea peroxide solution
Trial: 277069
Drug: Normal oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal oral hygiene instructions
Trial: 23438496
Drug: 45-g whey
RxNorm normalized name: tolnaftate
DrugBank: Tolnaftate (DB00525)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 45-g whey supplement
Trial: 23438496
Drug: 45-g maltodextrin
RxNorm normalized name: tolnaftate
DrugBank: Tolnaftate (DB00525)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 45-g maltodextrin control
Trial: 20861415
Drug: Propofol infusion
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol infusion based on lean body weight (LBW)
Trial: 20861415
Drug: Propofol infusion
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol infusion based on total body weight (TBW)
Trial: 20861415
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving propofol infusion based on total body weight (TBW)
Trial: 16516954
Drug: 0.4 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 g/kg alcohol dose
Trial: 14739053
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (repaglinide plus pioglitazone)
Trial: 7965263
Drug: Losartan (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan (150 mg)
Trial: 3111914
Drug: sorbinil (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sorbinil (125 mg daily for 6 mo)
Trial: 26136485
Drug: Triamcinolone hexacetonide
RxNorm normalized name: Triamcinolone Hexacetonide
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triamcinolone hexacetonide (TH) 40 mg IA injection
Trial: 26136485
Drug: Methylprednisolone acetate
RxNorm normalized name: methylprednisolone acetate
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone acetate (MA) 40 mg IA injection
Trial: 21414223
Drug: Intracoronary injection
RxNorm normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary injection of autologous mononuclear bone marrow cells (mBMC)
Trial: 16940835
Drug: Mebendazole (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mebendazole (500 mg single dose) plus iron supplements
Trial: 12898818
Drug: Psychotherapy as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychotherapy as a completion of traditional treatment for vocal nodules
Trial: 9952383
Drug: HBY 097
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBY 097 monotherapy (250 mg three times daily)
Trial: 9952383
Drug: Zidovudine plus
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zidovudine plus HBY 097 (750 mg three times daily)
Trial: 9952383
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with high‐dose HBY 097
Trial: 1970427
Drug: Clozapine (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clozapine (75 to 250 mg/day, mean 170.8)
Trial: 6993250
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of oxprenolol and hydralazine
Trial: 31993819
Drug: Doxapram (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxapram (1 mg/kg bolus and 1 mg/kg/h infusion)
Trial: 29800299
Drug: Standard 18-gauge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard 18-gauge peripheral intravenous catheter
Trial: 24612629
Drug: Integrated Psychological
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrated Psychological Intervention (IPI), including cognitive behaviour therapy for 12 months
Trial: 25381560
Drug: TNFi therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNFi therapy etanercept (ETN) combined with methotrexate (MTX)
Trial: 25381560
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy with MTX with or without additional synthetic disease modifying anti-rheumatic drugs
Trial: 23006447
Drug: Pemetrexed (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed (500 mg/m2 every 21 days) plus best supportive care (BSC)
Trial: 23006447
Drug: Pemetrexed (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed (500 mg/m2 every 21 days) plus BSC
Trial: 21090832
Drug: Telmisartan 40
RxNorm normalized name: telmisartan 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan 40 or 80 mg/day plus amlodipine 5 or 10 mg/day
Trial: 21090832
Drug: Single-pill telmisartan/amlodipine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-pill telmisartan/amlodipine
Trial: 21090832
Drug: Telmisartan or
RxNorm normalized name: telmisartan Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan or amlodipine monotherapy
Trial: 16166930
Drug: Azithromycin, 500
RxNorm normalized name: Azithromycin, 500 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin, 500 mg per os 1 hour prior to the procedure
Trial: 12013195
Drug: Aspirin 10%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 10%
Trial: 12013195
Drug: Aspirin 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 1%
Trial: 10413273
Drug: Higher-dose platelet
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher-dose platelet component (HDP)
Trial: 10413273
Drug: Lower-dose platelet
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower-dose platelet component (LDP)
Trial: 2197381
Drug: Meclofenamate 100
RxNorm normalized name: meclofenamate 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meclofenamate 100 mg plus codeine 60 mg
Trial: 2197381
Drug: Meclofenamate 50
RxNorm normalized name: meclofenamate 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meclofenamate 50 mg plus codeine 30 mg
Trial: 8284070
Drug: Meclofenamate 100
RxNorm normalized name: meclofenamate 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meclofenamate 100 mg
Trial: 6992844
Drug: 0.1% halcinonide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% halcinonide cream applied three times daily
Trial: 28244718
Drug: Hibiscus sabdariffa
RxNorm normalized name: HIBISCUS SABDARIFFA CALYX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hibiscus sabdariffa L. (HS) tea for 30 days
Trial: 24676694
Drug: 0.035 mg
RxNorm normalized name: vanadium 0.035 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.035 mg ethinyl estradiol + 2 mg cyproterone acetate (group A)
Trial: 24676694
Drug: 0.03 mg
RxNorm normalized name: biotin 0.03 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.03 mg ethinyl estradiol + 3 mg drospirenone (group B)
Trial: 17938746
Drug: Dental amalgam
RxNorm normalized name: DENTAL AMALGAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dental amalgam treatment
Trial: 17938746
Drug: Resin composite
RxNorm normalized name: Benzoin resin
DrugBank: Benzoin resin (DB11222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resin composite treatment
Trial: 10225582
Drug: Intravenous ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ciprofloxacin (400 mg, every 8 h)
Trial: 10225582
Drug: Intravenous standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous standard therapy (beta-lactam)
Trial: 10225582
Drug: Intravenous ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ciprofloxacin (400 mg, every 8 h) plus beta-lactam
Trial: 10225582
Drug: Intravenous standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous standard therapy (aminoglycoside plus beta-lactam)
Trial: 10225582
Drug: Ciprofloxacin (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (750 mg, every 12 h)
Trial: 10225582
Drug: Standard oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard oral therapy
Trial: 30499929
Drug: In the
RxNorm normalized name: Skin Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the Classroom Web site (treatment group)
Trial: 25751673
Drug: Isotonic intravenous
RxNorm normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isotonic intravenous fluids (sodium chloride, 0.9%, and dextrose, 5%)
Trial: 25751673
Drug: Hypotonic intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypotonic intravenous fluids (sodium chloride, 0.45%, and dextrose, 5%)
Trial: 25751673
Drug: Hypotonic intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypotonic intravenous fluids
Trial: 25751673
Drug: Isotonic intravenous
RxNorm normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isotonic intravenous fluids
Trial: 24331798
Drug: Tirofiban (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tirofiban (10 µg/kg bolus within 3 min followed by 0.10‐0.15 µg×kg(‐1)×min(‐1) for 36 h i.v.)
Trial: 20347467
Drug: Abstinence with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abstinence with transdermal nicotine patch (TNP)
Trial: 18554238
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg entecavir
Trial: 21794296
Drug: Overall NSAID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall NSAID therapy
Trial: 10971602
Drug: Brain-derived neurotrophic
RxNorm normalized name: brain-derived neurotrophic factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brain-derived neurotrophic factor (BDNF) 25 microg/kg daily
Trial: 8285335
Drug: 4 l.min‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 l.min‐1 of oxygen by nasal catheter
Trial: 3104180
Drug: Transdermal nitroglycerin
RxNorm normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal nitroglycerin patches delivering 10 mg/24 hours
Trial: 24786196
Drug: Jitai tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jitai tablet treatment
Trial: 20466951
Drug: Dental practitioner
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dental practitioner advice and brief counseling intervention including nicotine replacement therapy
Trial: 12554916
Drug: Vitamin K
RxNorm normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K prophylaxis in severely ill patients on extended periods of antibiotics and inadequate diet
Trial: 6366137
Drug: 5 years
RxNorm normalized name: Dymadon 5 Years Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 years of chemotherapy
Trial: 29787831
Drug: Oleoylethanolamide (OEA)
RxNorm normalized name: Palmitoylethanolamide
DrugBank: Oleic monoethanolamide (DB16495)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oleoylethanolamide (OEA) 125 mg capsules, two capsules daily for 60 days
Trial: 17557985
Drug: Green tea
RxNorm normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green tea extract (GTE) high in catechins (583 mg of catechins per day)
Trial: 17557985
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (96 mg of catechins per day)
Trial: 12189112
Drug: bisoprolol (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bisoprolol (5 mg/d)
Trial: 12189112
Drug: enalapril (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: enalapril (10 mg/d)
Trial: 12189112
Drug: nifedipine retard
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: nifedipine retard (20 mg/day)
Trial: 7661122
Drug: 90 mg
RxNorm normalized name: papain 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 mg beta-carotene daily for 3 weeks
Trial: 7661122
Drug: 120 mg
RxNorm normalized name: papain 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg beta-carotene oral dose
Trial: 1096541
Drug: Flupenthixol decanoate
RxNorm normalized name: flupenthixol decanoate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flupenthixol decanoate (parenteral)
Trial: 1096541
Drug: Both drugs
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both drugs (penfluridol and flupenthixol decanoate)
Trial: 25950433
Drug: 2011/12 seasonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2011/12 seasonal influenza DNA vaccine prime
Trial: 21563210
Drug: Anticholinergic medication
RxNorm normalized name: Anticholinergics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticholinergic medication with or without behavioral therapy